切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2010, Vol. 04 ›› Issue (02) : 132 -134. doi: 10.3877/cma.j.issn.1674-0793.2010.02.012

所属专题: 文献

论著

谷氨酰胺对胃癌术后化疗患者肠屏障功能的影响
赵晓雷1,(), 何效东1, 崔泉1, 邓志云1, 杨毅1   
  1. 1. 518029 深圳,武警广东边防总队医院外一科
  • 收稿日期:2009-10-16 出版日期:2010-04-01
  • 通信作者: 赵晓雷

Effects of glutamine on intestinal barrier function in patients undergoing postoperative chemotherapy for gastric cancer

Xiao-lei ZHAO1,(), Xiao-dong HE1, Quan CUI1, Zhi-yun DENG1, Yi YANG1   

  1. 1. General Hospital of Guangdong Police Frontier Defense, Shenzhen 518029, China
  • Received:2009-10-16 Published:2010-04-01
  • Corresponding author: Xiao-lei ZHAO
  • About author:
    Corresponding author: ZHAO Xiao-lei, Email:
引用本文:

赵晓雷, 何效东, 崔泉, 邓志云, 杨毅. 谷氨酰胺对胃癌术后化疗患者肠屏障功能的影响[J]. 中华普通外科学文献(电子版), 2010, 04(02): 132-134.

Xiao-lei ZHAO, Xiao-dong HE, Quan CUI, Zhi-yun DENG, Yi YANG. Effects of glutamine on intestinal barrier function in patients undergoing postoperative chemotherapy for gastric cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2010, 04(02): 132-134.

目的

观察谷氨酰胺对胃癌术后化疗患者肠屏障功能的影响。

方法

40例胃癌术后第4次化疗患者随机分为对照组和试验组,化疗方案为氟尿嘧啶(5-FU)、四氢叶酸(CF)加奥沙利铂(FOLFOX方案)。试验组化疗同时口服谷氨酰胺(30 g/d),对照组化疗时未口服谷氨酰胺,检测两组患者化疗前后血浆谷氨酰胺浓度、二胺氧化酶(DAO)、D-乳酸水平及粪便中肠道菌群情况。

结果

化疗后对照组血浆谷氨酰胺浓度较化疗前明显降低(P<0.05),试验组增加并明显高于对照组(P<0.01);化疗后两组血浆DAO水平较化疗前均明显升高(P<0.01),对照组较试验组升高更为明显(P<0.05);对照组D-乳酸水平化疗后升高(P<0.05),与试验组比较差异有统计学意义;试验组患者各肠道菌群总数化疗前后无明显变化,肠道菌群接近正常比例;对照组双歧杆菌、乳杆菌较化疗前明显下降(P<0.01),大肠埃希菌、肠球菌明显升高(P<0.01)。

结论

口服谷氨酰胺可提高胃癌术后化疗患者血浆谷氨酰胺浓度,有减轻损伤、调节肠道菌群微生态平衡、保护肠屏障功能的作用。

Objective

To study the effects of glutamine on intestinal barrier function in patients undergoing postoperative chemotherapy for gastric cancer.

Methods

Forty patients with gastric cancer after operation who accepted the fourth chemotherapy were randomly divided into Gln group and control group. The former received oral administration of glutamine (30 g/d) for 7 days. All patients received CF+5-FU+Oxalipatin chemotherapy, namely FOLFOX formula, for 5 days. Serum concentration of glutamine, DAO and D-lactate were measured before and l day after chemotherapy. Changes of microflora in stool were also studied by bacterial culture.

Results

After chemotherapy, the serum concentration of glutamine was significantly decreased in the control group(P<0.05)and increased in the Gln group(P<0.01), and there was significant difference between the two groups(P<0.01). The levels of DAO in the two groups after chemotherapy were significantly higher than those before treatment(P<0.01), while they were significantly higher in the control group than those in the Gln group(P<0.05). The levels of D-lactate in the control group were significantly higher than those in the Gln group(P<0.05). Bacterial culture revealed that the amount of bifidobaterium and lactobacilli were markedly increased while escherichia coli and enterococcus faecalis decreased in the control group.

Conclusion

Oral administration of glutamine can increase serum concentration of glutamine in chemotherapy patients with gastric cancer and shows the protective effects on gut barrier function by alleviating the damage of intestinal mucosa and microecologic disturbance.

表1 40例胃癌患者化疗前后血浆谷氨酰胺浓度、DAO及D-乳酸活性变化(±s
表2 40例胃癌患者化疗前后肠道菌群变化(ln/g,±s
1
Kwon C, Seung S, Suk J, et al. The effect of oral glutamine on 5-fluoro uracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr, 2007, 10(5):639-659.
2
李仲南,汪昱,秦环龙. 化疗药物对肠屏障功能的损伤机制及防治进展. 山东医药,2008,48(26):113-115.
3
邓宇,许瑞云,刘波等. Gln与rhGh对肝硬化病人肠黏膜屏障的影响. 中国现代医学杂志, 2006, 16(15):2336-2338.
4
果磊,黄崇本. 谷氨酰胺在肠道的代谢及其作用. 中国药房, 2005, 16(4):305-307.
5
XI P, HONG Y, ZHONG YY, et al. Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients. Burns, 2004, 30(1):135-139.
6
Erick V, Angelam M, Gil H. Impact of oral L-glutamine on glutathione, glutamine, and glutamate blood levels in volunteers. Nutrition, 2002, 18(2):367-370.
[1] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[2] 张华, 孙宇, 乡世健, 李樱媚, 王小群. 循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2023, 17(06): 422-425.
[3] 张再博, 王冰雨, 焦志凯, 檀碧波. 胃癌术后下肢深静脉血栓危险因素的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 475-480.
[4] 张焱辉, 张蛟, 朱志贤. 留置肛管在中低位直肠癌新辅助放化疗后腹腔镜TME术中的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 25-28.
[5] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[6] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[7] 汪洋, 李志鹏, 王可兵. 上尿路尿路上皮癌术后预防性膀胱灌注化疗的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 649-652.
[8] 刘恒, 侯宇川. 膀胱癌新型灌注药物的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 445-451.
[9] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[10] 韩晓娟, 徐佳倩, 朱玉兰, 王莹, 李源, 冯珺, 邵东. HHLA2过表达胃癌细胞株构建及细胞功能的初步研究[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 373-377.
[11] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[12] 孙秀艳, 徐庆蕾, 马鹏涛, 胡志元, 郭传真, 祝成红. 腹腔镜胃癌根治术中患者体温变化与压力性损伤及受压部位微环境的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 480-484.
[13] 杨镠, 秦岚群, 耿茜, 李栋庆, 戚春建, 蒋华. 可溶性免疫检查点对胃癌患者免疫治疗疗效和预后的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 305-311.
[14] 董青, 丁飞, 郭浩, 李峰. Nesfatin-1/NUCB2在幽门螺杆菌感染相关早期胃癌患者中的表达及临床意义[J]. 中华临床医师杂志(电子版), 2023, 17(07): 783-789.
[15] 牛文博, 吴凤鹏, 刘月平, 周超熙, 张娟, 胡旭华, 李保坤, 王贵英. 新辅助放化疗对局部进展期直肠癌疗效及肿瘤免疫微环境变化的研究[J]. 中华临床医师杂志(电子版), 2023, 17(05): 519-523.
阅读次数
全文


摘要